InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2025)
Historic Return on Capital Employed for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to 0.62%.
- InMed Pharmaceuticals' Return on Capital Employed rose 1300.0% to 0.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.62%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 0.67% for FY2025, which is 800.0% up from last year.
- According to the latest figures from Q3 2025, InMed Pharmaceuticals' Return on Capital Employed is 0.62%, which was up 1300.0% from 0.75% recorded in Q2 2025.
- In the past 5 years, InMed Pharmaceuticals' Return on Capital Employed registered a high of 0.52% during Q1 2024, and its lowest value of 1.73% during Q3 2022.
- Moreover, its 4-year median value for Return on Capital Employed was 0.76% (2024), whereas its average is 0.94%.
- Per our database at Business Quant, InMed Pharmaceuticals' Return on Capital Employed soared by 10500bps in 2023 and then crashed by -6400bps in 2025.
- InMed Pharmaceuticals' Return on Capital Employed (Quarter) stood at 1.19% in 2022, then skyrocketed by 49bps to 0.61% in 2023, then tumbled by -68bps to 1.02% in 2024, then surged by 39bps to 0.62% in 2025.
- Its last three reported values are 0.62% in Q3 2025, 0.75% for Q2 2025, and 1.16% during Q1 2025.